Address :
Hidoc Dr. Inc. | Delaware C Corp | 1309 Coffeen Ave. Suite 1200, Sheridan WY, 82801
Phone :
+1-415-463-3094
Email :
anishagadia@hidoc.co
Published Date: 06 Mar 2023
USA: The syrup drug Diethylene glycol (DEG), a drug commonly used to prevent infections, is the cause of kidney disease...
Read Full News(This Aug 27 story has been republished, with no changes to text.)
Barriers to blood donations from Black people in Canada are rooted in racism and restrictive policies.
After biochemical recurrence, hypofractionated RT may be no more effective than standard RT for disease control — and may have more late side effects.
Researchers followed 787 patients with brain tumors treated with laser therapy for up to 5 years.
Ibrutinib improves event-free survival in certain genetic subgroups of early-stage chronic lymphocytic leukemia but fails to extend overall survival.
1.
The risk of ovarian cancer is not increased by salpingectomy, according to JAMA.
2.
What is a "cancer vaccine" and is it the same as a COVID vaccine?
3.
Predicting adult mortality from oral cancer using a machine learning approach.
4.
DNA's hidden shape reveals target to reverse ovarian cancer chemoresistance
5.
Studies show that treatment for non-Hodgkin's lymphoma is also focused on the lymphoma.
1.
Federated Hematology Data Networks for Collaborative Research Without Centralized Patient-Level Data
2.
Liquid Biopsies Unveiling the Future of Precision Cancer Management by 2025
3.
Understanding the Importance of CA125: A Comprehensive Guide
4.
Cerebrospinal Fluid Metabolite Biomarkers in Central Nervous System Tumor Monitoring: A New Frontier
5.
HSC Failure in Fanconi Anemia: Mechanisms, Models, and Emerging Therapeutic Pathways
1.
Asian Symposium on Advancement in Hematology and Oncology (ASAHO)
2.
International Cancer Conference
3.
Asian Symposium on Advancement in Hematology and Oncology (ASAHO)
4.
Asian Symposium on Advancement in Hematology and Oncology
5.
Asian Symposium on Advancement in Hematology and Oncology
1.
Pazopanib: A Game-Changer in Managing Advanced Renal Cell Carcinoma - Part IV
2.
Navigating the Complexities of Ph Negative ALL - Part V
3.
Navigating the Brain Barrier: The CNS Challenge in ALK+ NSCLC
4.
CDK4/6 Inhibitors Redefining Treatment for HR+/HER2- aBC In Post-Menopausal Women- A Panel Discussion
5.
Current Scenario of Cancer- Q&A Session to Close the Gap
Address :
Hidoc Dr. Inc. | Delaware C Corp | 1309 Coffeen Ave. Suite 1200, Sheridan WY, 82801
Phone :
+1-415-463-3094
Email :
anishagadia@hidoc.co
© Copyright 2026 Hidoc Dr. Inc.
Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
To get started please enter your email ID
Join to enhance your clinical skills and gain specialized in-depth medical knowledge